50 stories mentioning BIIBUpdated 1h ago
Every FINWIRES story that references BIIB, newest first.
Biogen (BIIB) has an average rating of overweight and mean price target of $235.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $204.33, Change: $-4.90, Percent Change: -2.34%
Biogen (BIIB) has an average rating of overweight and mean price target of $235.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $204.20, Change: $-5.03, Percent Change: -2.40%
Biogen (BIIB) has an average rating of overweight and mean price target of $235.24, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $206.33, Change: $-2.91, Percent Change: -1.39%
Biogen (BIIB) has an average rating of overweight and mean price target of $230.32, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $207.41, Change: $+1.80, Percent Change: +0.88%
Biogen (BIIB) has an average rating of overweight and mean price target of $230.32, according to analysts polled by FactSet.Price: $210.62, Change: $+5.01, Percent Change: +2.43%
Biogen (BIIB) has an average rating of overweight and mean price target of $230.32, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $211.30, Change: $+5.69, Percent Change: +2.77%
Biogen's (BIIB) Q2 results beat was supported by the company's recent acquisition of Apellis, Wedbush Securities said in a note Wednesday.Biogen's Q2 total revenue of $2.736 billion was higher than consensus estimates at $2.462 billion as the company's product revenue included about $208 million in Apellis-linked revenue, the note said.Wedbush noted that after the acquisition, Biogen lowered its 2026 non-GAAP earnings per share guidance to $12.00 to $13.00 from the previous guidance of $14.25 to $15.25, partly reflecting a negative impact from Apellis charges, the note said.Wedbush said, however, the Q2 beat was a positive factor for the stock, while the guidance revision after the Apellis deal "seems as anticipated.""With management continuing to indicate accretion in 2027, we think this should be reassuring," the note said, with unlocking additional revenue growth drivers most important.Wedbush kept its neutral rating on Biogen and has a $201 price target on the company.Price: $216.33, Change: $+10.72, Percent Change: +5.21%
Biogen (BIIB) has an average rating of overweight and mean price target of $224.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $191.24, Change: $-17.80, Percent Change: -8.51%
Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%
Healthcare stocks fell late Thursday afternoon with the NYSE Healthcare Index dropping 1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.9%.The iShares Biotechnology ETF (IBB) shed 0.3%.In corporate news, Pfizer (PFE) shares dropped 2.5% after the company reaffirmed its fiscal 2026 guidance. The company also said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 1.4%.EnGene (ENGN) shares shed 1.4% after Morgan Stanley downgraded the stock to underweight from equalweight.NovoCure (NVCR) shares tumbled 19% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.
Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) declining 0.8%.The iShares Biotechnology ETF (IBB) shed 0.5%.In corporate news, Pfizer (PFE) shares fell 2.6% after the company said Chief Financial Officer Dave Denton will step down on Aug. 15 after accepting a position in the consumer-goods sector.Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 1.9%.NovoCure (NVCR) shares dropped 19% after the company said a phase 3 trial evaluating its tumor treating fields therapy in patients with newly diagnosed glioblastoma failed to meet its primary endpoint.Kardigan (KARD) shares surged 28% to $20.50 in their debut on the Nasdaq. The clinical-stage precision therapeutics company priced its initial public offering of 25 million shares at $16 each. Underwriters were granted a 30-day option to purchase an additional 3.75 million shares.
Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each declining 1%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion. Biogen shares fell 2%.
Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 billion as the firm aims to strengthen its immunology portfolio.Shareholders of RayThera, which develops small-molecule therapies in immunology, will receive an upfront payment from Biogen, according to a late Wednesday joint statement by the companies. The shareholders will also be eligible to receive certain clinical and regulatory milestone payments in the future, the companies said.Biogen's stock was up 0.5% in Thursday's premarket activity, having closed the previous session with a 1.6% gain.RayThera's portfolio includes several anti-inflammatory assets to potentially treat immune-mediated conditions. The firm's lead candidate is expected to enter phase 1 development early in the third quarter."With this acquisition, we are further deepening our pipeline in immunology by adding a suite of assets that can allow us to expand into new disease areas," Biogen's head of development, Priya Singhal, said. "We believe these assets can meaningfully contribute to our long-term pipeline potential and we're excited about the opportunity to rapidly advance the first candidate into the clinic."The transaction, which requires approval from regulators, is expected to complete in the third quarter. Following completion, Biogen intends to lead the development, manufacturing and global commercialization of RayThera's assets."With its strong global development capabilities in immunology, we believe that Biogen is the natural fit to move these assets forward into phase 1 development and beyond," according to RayThera Chief Executive Qing Dong.In March, Biogen agreed to purchase biopharmaceutical firm Apellis Pharmaceuticals (APLS), strengthening its immunology and rare disease portfolio and accelerating its expansion into nephrology. The deal had a total cash consideration of $5.6 billion.
Biogen (BIIB) has an average rating of overweight and mean price target of $219.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Healthcare stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.5% higher and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Biogen (BIIB) shares were up more than 1% after the company said the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.Royal Philips (PHG) and WellSpan Health said they have entered into a seven-year partnership focused on research, innovation, and the deployment of advanced imaging and diagnostic technologies across WellSpan's network. Shares of Royal Philips were up more than 1% pre-bell.Amneal Pharmaceuticals (AMRX) stock was 1% higher after the company said has received the US Food and Drug Administration's approval for its romidepsin injection solution.
Healthcare stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.5% higher and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Biogen (BIIB) shares were up more than 1% after the company said the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.
Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.6% higher and the iShares Biotechnology ETF (IBB) down 0.1%.Biogen (BIIB) and Denali Therapeutics (DNLI) are discontinuing further development of BIIB122 in idiopathic Parkinson's disease after a phase 2b study failed to meet its primary or secondary endpoints, the companies said. Biogen shares were down 1% and Denali Therapeutics stock lost more than 3% pre-bell.Medline (MDLN) shares were up more than 1% after the company priced its upsized secondary offering of about 72.6 million of its class A shares on behalf of certain selling stockholders at $37 apiece.Gilead Sciences (GILD) said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of Trodelvy as a first-line treatment for certain patients with metastatic triple-negative breast cancer. Gilead Sciences shares were 0.4% higher pre-bell.
Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% higher and the iShares Biotechnology ETF (IBB) down 0.1%.Biogen (BIIB) and Denali Therapeutics (DNLI) are discontinuing further development of BIIB122 in idiopathic Parkinson's disease after a phase 2b study failed to meet its primary or secondary endpoints, the companies said. Biogen shares were down 1% and Denali Therapeutics stock lost more than 3% pre-bell.
US equity indexes ended higher on Thursday as technology stocks led major gains in the Nasdaq and the S&P 500, pushing them toward new all-time highs.* Among the top 10 companies with a market capitalization of more than $200 billion, implying a significant sway over indexes, eight were from the technology sector. In the S&P 500 and Nasdaq, Cisco Systems (CSCO) was the top outperformer.* Retail sales in April rose for the third straight month, up 0.5% following a revised 1.6% gain in March, the Census Bureau reported Thursday, matching the consensus in a survey compiled by Bloomberg.* June West Texas Intermediate crude oil rose $0.81 to settle at $101.83 per barrel, while July Brent crude, the global benchmark, was last seen up $0.74 at $106.37.* Cisco (CSCO) shares were up roughly 13% after the company reported a year-over-year rise in fiscal Q3 earnings and revenue, beating market expectations, and raised its fiscal 2026 guidance. The firm also announced restructuring plans that included lay-offs of nearly 4,000 employees.* Biogen (BIIB) shares were down 6.4% after the company said a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.
Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally higher.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Prestige Consumer Healthcare's (PBH) officials said Thursday that weak eye care sales and a difficult consumer backdrop drove disappointing fiscal Q4 results at the consumer healthcare products company. Its shares were down past 11%.Biogen (BIIB) shares fell nearly 7% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 23%.Aveanna Healthcare (AVAH) shares jumped past 8% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.
Showing 1-20 of 50
